Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Catalyst Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ACHIEVED RECORD Q2 2025 TOTAL REVENUES OF $146.6 MILLION, AN INCREASE OF 19.4% YO Y, MARKING ANOTHER QUARTER OF CONSECUTIVE GROWTH REPORTED RECORD FIRST HALF 2025 TOTAL REVENUES OF $288.0 MILLION, AN INCREASE OF 30.2% OVER PRIOR YEAR REAFFIRMS FULL-YEAR 2025 TOTAL REVENUE GUIDANCE OF $545 MILLION TO $565 MILLION, REFLECTING BROAD-BASED GROWTH AND SUSTAINED DEMAND FIRDAPSE Q2 2025 NET PRODUCT REVENUE OF $84.8 MILLION, UP 9.7% YOY; FIRST HALF 2025 NET PRODUCT REVENUE OF $168.6 MILLION, A 16.9% INCREASE OVER PRIOR YEAR, UNDERSCORING SUSTAINED MOMENTUM AND CONFIDENCE IN LONG-TERM GROWTH AGAMREE Q2 2025 NET PRODUCT REVENUE OF $27.4 MILLION, UP 212.9% YOY; FIRST HALF 2025 NET PRODUCT REVENUE OF $49.4 MILLION, A 398.0% INCREASE OVER PRIOR YEAR, HIGHLIGHTING CONTINUED PRODUCT MOMENTUM FYCOMPA Q2 2025 NET PRODUCT REVENUE OF $34.3 MILLION ; SLIGHT DECREASE YOY DUE TO GENERIC ENTRY FOLLOWING LOSS OF EXCLUSIVITY STRONG CASH POSITION OF $652.8 MILLION AND NO FUNDED DEBT AT THE END OF Q2 2025 CONFERENCE CALL AND WEBCAST TO BE HELD ON AUGUST 7, 2025, AT 8:30 AM ET CORAL GABLES, FLA., AUG. 06, 2025 (GLOBE NEWSWIRE) -- CATALYST PHARMACEUTICALS, INC.("CATALYST" OR "COMPANY") (NASDAQ: CPRX), TODAY REPORTED RECORD FINANCIAL RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2025, AND PROVIDED A BUSINESS UPDATE.

CATALYST PHARMACEUTICALS REPORTS RECORD SECOND QUARTER AND FIRST HALF 2025 FINANCIAL RESULTS; PROVIDES BUSINESS UPDATE

CORAL GABLES, FLA., AUG. 06, 2025 (GLOBE NEWSWIRE) -- CATALYST PHARMACEUTICALS, INC. ("CATALYST" OR "COMPANY") (NASDAQ: CPRX), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON IN-LICENSING, DEVELOPING, AND COMMERCIALIZING NOVEL MEDICINES FOR PATIENTS LIVING WITH RARE AND DIFFICULT-TO-TREAT DISEASES, TODAY ANNOUNCED THE NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (NCCN GUIDELINES) FOR SMALL CELL LUNG CANCER (SCLC) NOW INCLUDE NEW ADDITIONS INVOLVING LAMBERT EATON MYASTHENIC SYNDROME (LEMS), AMIFAMPRIDINE (FIRDAPSE), AND THE TESTS FOR PQ- AND N-TYPE VOLTAGE-GATED CALCIUM CHANNEL (VGCC) ANTIBODIES.

LAMBERT EATON MYASTHENIC SYNDROME (LEMS) ANTIBODY TESTING AND TREATMENT RECOMMENDATIONS ADDED TO NCCN CLINICAL PRACTICE GUIDELINES FOR SMALL CELL LUNG CANCER (SCLC)

CORAL GABLES, FLA., AUG. 04, 2025 (GLOBE NEWSWIRE) -- CATALYST PHARMACEUTICALS, INC. ("CATALYST" OR "COMPANY") (NASDAQ: CPRX) TODAY ANNOUNCED THE APPOINTMENT OF DANIEL CURRAN, MD, TO ITS BOARD OF DIRECTORS.

CATALYST PHARMACEUTICALS APPOINTS DANIEL CURRAN, MD, TO ITS BOARD OF DIRECTORS

THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST ON THURSDAY, AUGUST 7, 2025, AT 8:30 AM ET THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST ON THURSDAY, AUGUST 7, 2025, AT 8:30 AM ET

CATALYST PHARMACEUTICALS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 6, 2025

GARY INGENITO, MD, PHD IS RETIRING FROM CATALYST AFTER A SUCCESSFUL CAREER GARY INGENITO, MD, PHD IS RETIRING FROM CATALYST AFTER A SUCCESSFUL CAREER

CATALYST PHARMACEUTICALS ANNOUNCES APPOINTMENT OF WILLIAM T. ANDREWS, MD, FACP AS CHIEF MEDICAL OFFICER

CATALYST ENTERS 2025 WITH STRONG MOMENTUM; REITERATES CONFIDENCE IN FULL-YEAR OUTLOOK DELIVERS RECORD Q1 2025 TOTAL REVENUES OF$141.4 MILLION, A 43.6% YOY INCREASE FIRDAPSE AND AGAMREE DRIVE SUSTAINED ORGANIC GROWTH, UNDERSCORING EXECUTION STRENGTH REAFFIRMS FULL-YEAR 2025 TOTAL REVENUE GUIDANCE PROVIDED EARLIER THIS YEAR OF BETWEEN $545 MILLION AND $565 MILLION STRENGTHENS BALANCE SHEET WITH CASH AND CASH EQUIVALENTS OF $580.7 MILLION AND NO DEBT AS OF MARCH 31, 2025 CONFERENCE CALL AND WEBCAST TO BE HELD ON MAY 8, 2025, AT 8:30 AM ET CORAL GABLES, FLA., MAY 07, 2025 (GLOBE NEWSWIRE) -- CATALYST PHARMACEUTICALS, INC.("CATALYST" OR "COMPANY") (NASDAQ: CPRX), TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2025 AND PROVIDED A BUSINESS UPDATE.

CATALYST PHARMACEUTICALS REPORTS RECORD FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CORAL GABLES, FLA., APRIL 30, 2025 (GLOBE NEWSWIRE) -- CATALYST PHARMACEUTICALS, INC.(CATALYST OR COMPANY) (NASDAQ: CPRX), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON IN-LICENSING, DEVELOPING, AND COMMERCIALIZING NOVEL MEDICINES FOR PATIENTS LIVING WITH RARE AND DIFFICULT-TO-TREAT DISEASES, TODAY ANNOUNCED THATRICHARD J. DALY, PRESIDENT AND CEO OF CATALYST, ALONG WITH OTHER MEMBERS OF CATALYST'S MANAGEMENT TEAM, WILL PARTICIPATE AT THE UPCOMING BOFA SECURITIES HEALTH CARE CONFERENCE 2025 ON WEDNESDAY, MAY 14, 2025, AT THE ENCORE HOTEL, LAS VEGAS, NEVADA.

CATALYST PHARMACEUTICALS TO PARTICIPATE IN THE BOFA SECURITIES HEALTH CARE CONFERENCE 2025

THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST ON MAY 8, 2025, AT 8:30 AM ET THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST ON MAY 8, 2025, AT 8:30 AM ET

CATALYST PHARMACEUTICALS TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ON MAY 7, 2025

CORAL GABLES, FLA., APRIL 08, 2025 (GLOBE NEWSWIRE) -- CATALYST PHARMACEUTICALS, INC. ("CATALYST" OR "COMPANY") (NASDAQ: CPRX), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON IN-LICENSING, DEVELOPING, AND COMMERCIALIZING NOVEL MEDICINES FOR PATIENTS LIVING WITH RARE AND DIFFICULT-TO-TREAT DISEASES, TODAY REPORTED THAT ITS SUB-LICENSEE INCANADA,KYE PHARMACEUTICALS, INC. (KYE), HASANNOUNCED THAT HEALTH CANADA HAS ACCEPTED THE NEW DRUG SUBMISSION (NDS) FOR AGAMREE, A NOVEL CORTICOSTEROID TREATMENT FOR DUCHENNE MUSCULAR DYSTROPHY (DMD), FOR REVIEW. THE SUBMISSION HAS BEEN GRANTED PRIORITY REVIEW, EXPEDITING THE REGULATORY PROCESS WITH THE POTENTIAL FOR MARKETING AUTHORIZATION BEFORE THE END OF 2025. IF APPROVED, AGAMREE WOULD BE THE FIRST AND ONLY TREATMENT OPTION INDICATED FOR PATIENTS DIAGNOSED WITH DMD IN CANADA.

CATALYST PHARMACEUTICALS ANNOUNCES HEALTH CANADA'S ACCEPTANCE OF AGAMREE NEW DRUG SUBMISSION WITH PRIORITY REVIEW FOR SUB-LICENSEE KYE PHARMACEUTICALS

CORAL GABLES, FLA., MARCH 04, 2025 (GLOBE NEWSWIRE) -- CATALYST PHARMACEUTICALS, INC. ("CATALYST" OR "COMPANY") (NASDAQ: CPRX), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON IN-LICENSING, DEVELOPING, AND COMMERCIALIZING NOVEL MEDICINES FOR PATIENTS LIVING WITH RARE AND DIFFICULT-TO-TREAT DISEASES, TODAY ANNOUNCED THAT RICHARD J. DALY, PRESIDENT AND CEO OF CATALYST, ALONG WITH OTHER MEMBERS OF CATALYST'S MANAGEMENT TEAM, WILL PARTICIPATE IN THE UPCOMING BARCLAYS 27TH ANNUAL GLOBAL HEALTHCARE CONFERENCE ON TUESDAY, MARCH 11, 2025 BEING HELD IN MIAMI, FLORIDA.

Catalyst Pharmaceuticals, Inc.

CPRX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Catalyst Pharmaceuticals, Inc.

CPRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CPRX